Caribou Biosciences: Advancing Allogeneic Cell Therapy Pipeline and Pivotal Trial Plans Support High-Risk Buy Rating

NodeGuardian · 2026-03-07T18:46:21+00:00

Citi's Yigal Nochomovitz maintains a Buy rating for Caribou Biosciences, setting an $8 target, highlighting its clinical advancements and regulatory clarity. The company is advancing trials in lymphoma and has sufficient cash reserves until late 2027.

NodeGuardian

2026-03-07 18:46:21

Abstract generation in progress

Citi analyst Yigal Nochomovitz maintained a Buy rating on Caribou Biosciences (CRBU) with an $8.00 price target, citing the company’s advancing clinical pipeline and defined regulatory path. Caribou is progressing a pivotal Phase 2 trial for vispa-cel in second-line large B-cell lymphoma and expects longer-term data from the ANTLER Phase 1 trial this year. The company’s cash reserves of approximately $143 million are expected to fund operations into the second half of 2027, supporting key clinical milestones.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.